Drug
DS 8500a
DS 8500a: highest development phase Phase 2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS-8500a 25 mg NCT02685345 | Phase 2 | Type 2 Diabetes Mellitus |
Latest
No recent events.
Follow DS 8500a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.